JP2013514367A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013514367A5 JP2013514367A5 JP2012544740A JP2012544740A JP2013514367A5 JP 2013514367 A5 JP2013514367 A5 JP 2013514367A5 JP 2012544740 A JP2012544740 A JP 2012544740A JP 2012544740 A JP2012544740 A JP 2012544740A JP 2013514367 A5 JP2013514367 A5 JP 2013514367A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- salt according
- items
- ring
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28676509P | 2009-12-15 | 2009-12-15 | |
| US61/286,765 | 2009-12-15 | ||
| PCT/US2010/060439 WO2011084453A1 (en) | 2009-12-15 | 2010-12-15 | Ppar-sparing thiazolidinedione salts for the treatment of metabolic diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013514367A JP2013514367A (ja) | 2013-04-25 |
| JP2013514367A5 true JP2013514367A5 (enExample) | 2013-06-06 |
| JP5634526B2 JP5634526B2 (ja) | 2014-12-03 |
Family
ID=43501294
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012544740A Active JP5634526B2 (ja) | 2009-12-15 | 2010-12-15 | 代謝性疾患を処置するためのｐｐａｒ温存チアゾリジンジオン塩 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US8912335B2 (enExample) |
| EP (1) | EP2513070B1 (enExample) |
| JP (1) | JP5634526B2 (enExample) |
| KR (3) | KR102029560B1 (enExample) |
| CN (1) | CN102753539B (enExample) |
| AU (1) | AU2010340055B2 (enExample) |
| CA (1) | CA2783468C (enExample) |
| DK (1) | DK2513070T3 (enExample) |
| ES (1) | ES2658168T3 (enExample) |
| HU (1) | HUE038042T2 (enExample) |
| MX (1) | MX2012006725A (enExample) |
| NO (1) | NO2513070T3 (enExample) |
| NZ (1) | NZ600390A (enExample) |
| PL (1) | PL2513070T3 (enExample) |
| RU (1) | RU2564661C2 (enExample) |
| WO (1) | WO2011084453A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102029560B1 (ko) | 2009-12-15 | 2019-10-07 | 씨리우스 테라퓨틱스, 엘엘씨 | 대사성 질환의 치료를 위한 ｐｐａｒ 절약형 티아졸리딘디온염 |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| MX2015008077A (es) | 2012-12-21 | 2015-10-30 | Sanofi Sa | Derivados de exendina-4 como agonistas dobles de glp1/gip o trigonal de glp1-gip/glucagon. |
| EP3024816B1 (en) | 2013-07-22 | 2020-06-03 | Metabolic Solutions Development Company LLC | Ppar-sparing compounds for the treatment of metabolic diseases |
| EP3080152A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Non-acylated exendin-4 peptide analogues |
| WO2015086733A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
| EP3080150B1 (en) | 2013-12-13 | 2018-08-01 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| WO2015086729A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/gip receptor agonists |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
| WO2019154958A1 (en) | 2018-02-08 | 2019-08-15 | Enyo Pharma | Use of modulators of neet proteins for the treatment of infection |
| CN111689934B (zh) * | 2020-06-24 | 2022-08-02 | 郑州大学 | 14-脱羟-13-脱氢穿心莲内酯-12-磺酸钾的单晶体及制备方法 |
| GB202210503D0 (en) | 2022-07-18 | 2022-08-31 | Univ Court Univ Of Glasgow | Materials and methods for treatment of chronic myeloid leukemia (CML) |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5522636A (en) | 1978-08-04 | 1980-02-18 | Takeda Chem Ind Ltd | Thiazoliding derivative |
| WO1985004170A1 (fr) | 1984-03-21 | 1985-09-26 | Takeda Chemical Industries, Ltd. | Derives de thiazolidinedione, leur procede de preparation et compositions medicinales les contenant |
| US4582839A (en) | 1984-03-21 | 1986-04-15 | Takeda Chemical Industries, Ltd. | 2,4-thiazolidinediones |
| CN1003445B (zh) | 1984-10-03 | 1989-03-01 | 武田药品工业株式会社 | 噻唑烷二酮衍生物，其制备方法和用途 |
| WO1986002073A1 (fr) | 1984-10-03 | 1986-04-10 | Takeda Chemical Industries, Ltd. | Derives de thiazolidinedione, procede de preparation et composition pharmaceutique les contenant |
| AR240698A1 (es) | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales |
| US5167228A (en) | 1987-06-26 | 1992-12-01 | Brigham And Women's Hospital | Assessment and modification of endogenous circadian phase and amplitude |
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5143930A (en) | 1990-02-07 | 1992-09-01 | Sankyo Company, Limited | Thiazolidine derivatives with anti-diabetic activity, their preparation and their use |
| US5356913A (en) | 1990-02-09 | 1994-10-18 | The Upjohn Company | Use of insulin sensitizing agents to treat hypertension |
| US5441971A (en) | 1991-04-11 | 1995-08-15 | The Upjohn Company | Thiazolidinedione derivatives, production and use thereof |
| EP0579733B1 (en) | 1991-04-11 | 2001-06-20 | PHARMACIA & UPJOHN COMPANY | Thiazolidinedione derivatives, production and use thereof |
| NO302471B1 (no) | 1991-12-26 | 1998-03-09 | Sankyo Co | Tiazolidinforbindelser og farmasöytisk preparat |
| US5716981A (en) | 1993-07-19 | 1998-02-10 | Angiogenesis Technologies, Inc. | Anti-angiogenic compositions and methods of use |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| TWI238064B (en) * | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
| CA2180296C (en) | 1995-07-03 | 2007-01-09 | Yoshio Tsujita | Treatment of arteriosclerosis and xanthoma |
| US7407978B2 (en) | 1999-04-06 | 2008-08-05 | Theracos, Inc. | Heterocyclic analogs of diphenylethylene compounds |
| WO2000066102A2 (en) | 1999-04-29 | 2000-11-09 | City Of Hope | Pentoxifylline, pioglitazone and metformin are inhibitors of formation of advanced glycation endproducts (age's) |
| US6331596B1 (en) | 1999-06-28 | 2001-12-18 | Basf Corporation | Method of preparing carbamate-functional polymers |
| NZ516455A (en) | 1999-06-30 | 2004-03-26 | Tularik Inc | Compounds for the modulation of PPARgamma activity |
| WO2001082916A2 (en) | 2000-05-03 | 2001-11-08 | Tularik Inc. | Combination therapeutic compositions and methods of use |
| US20040087484A1 (en) | 2000-12-01 | 2004-05-06 | Sahota Pritam Singh | Combination of organic compounds |
| EP1387843B1 (en) | 2001-04-26 | 2007-02-28 | Zentiva, a.s. | Method for obtaining pioglitazone as an antidiabetic agent |
| US7135485B2 (en) | 2001-09-28 | 2006-11-14 | Teva Pharmaceutical Industries Ltd. | Pioglitazone hydrochloride |
| AUPS236902A0 (en) | 2002-05-16 | 2002-06-13 | Northern Sydney Area Health Service | Composition and method for treating hypertension |
| WO2004007490A2 (en) * | 2002-07-16 | 2004-01-22 | Cadila Healthcare Limited | A process to prepare pioglitazone via several intermediates. |
| US20060083784A1 (en) | 2002-08-07 | 2006-04-20 | Smithkline Beecham Corporation | Amorphous pharmaceutical compositions |
| US7230016B2 (en) * | 2003-05-13 | 2007-06-12 | Synthon Ip Inc. | Pioglitazone salts, such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same |
| WO2005021542A2 (en) | 2003-08-28 | 2005-03-10 | Ranbaxy Laboratories Limited | Process for the preparation of pioglitazone |
| AR047541A1 (es) | 2004-02-13 | 2006-01-25 | Sandoz Ag | Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas |
| JP4475983B2 (ja) * | 2004-03-03 | 2010-06-09 | 学校法人日本大学 | Ｂｍａｌ１を阻害する方法 |
| BRPI0516219A (pt) | 2004-09-28 | 2008-08-26 | Otsuka Pharma Co Ltd | composto de carboestirila |
| AU2007227594B2 (en) | 2006-03-16 | 2012-11-15 | Metabolic Solutions Development Company, Llc | Thiazolidinedione analogues for the treatment of hypertension and for lowering lipids |
| CA2646170A1 (en) | 2006-03-16 | 2007-09-27 | Metabolic Solutions Development Company | Combination therapies of thiazolidinedione analogues and glucocorticoid agonists |
| CA2646207C (en) | 2006-03-16 | 2016-01-19 | Metabolic Solutions Development Company | Thiazolidinedione analogues for the treatment of metabolic inflammation mediated disease |
| WO2009038681A1 (en) * | 2007-09-14 | 2009-03-26 | Metabolic Solutions Development Company | Thiazolidinedione analogues for the treatment of hypertension |
| US8304441B2 (en) | 2007-09-14 | 2012-11-06 | Metabolic Solutions Development Company, Llc | Thiazolidinedione analogues for the treatment of metabolic diseases |
| US8722710B2 (en) | 2007-09-26 | 2014-05-13 | Deuterx, Llc | Deuterium-enriched pioglitazone |
| EP2222272B1 (en) | 2008-08-07 | 2012-11-07 | Pulmagen Therapeutics (Inflammation) Limited | Respiratory disease treatment |
| WO2010105048A1 (en) | 2009-03-12 | 2010-09-16 | Metabolic Solutions Development Company | Thiazolidinedione analogues |
| WO2011017244A1 (en) | 2009-08-05 | 2011-02-10 | Metabolic Solutions Development Company | Polymorphs of 5-(4-(2-(5-ethylpyridin-2-yl)-2-oxoethoxy)benzyl)-1,3-thiazolidine-2,4-dione (mitoglitazone) |
| AU2010331926B2 (en) | 2009-12-15 | 2014-03-27 | Cirius Therapeutics, Inc. | PPAR-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases |
| RU2012130011A (ru) | 2009-12-15 | 2014-01-27 | МЕТАБОЛИК СОЛЮШНЗ ДЕВЕЛОПМЕНТ КОМПАНИ, ЭлЭлСи | Ppar-снижающие тиазолидиндионы и комбинации для лечения сахарного диабета и других нарушений обмена веществ |
| EP2512475A1 (en) | 2009-12-15 | 2012-10-24 | Metabolic Solutions Development Company LLC | Ppar-sparing thiazolidinediones and combinations for the treatment of obesity and other metabolic diseases |
| KR102029560B1 (ko) | 2009-12-15 | 2019-10-07 | 씨리우스 테라퓨틱스, 엘엘씨 | 대사성 질환의 치료를 위한 ｐｐａｒ 절약형 티아졸리딘디온염 |
| EP2560615A1 (en) | 2010-04-21 | 2013-02-27 | Metabolic Solutions Development Company LLC | Thiazolidinedione analogues |
-
2010
- 2010-12-15 KR KR1020177010102A patent/KR102029560B1/ko active Active
- 2010-12-15 NZ NZ600390A patent/NZ600390A/xx unknown
- 2010-12-15 ES ES10796247.4T patent/ES2658168T3/es active Active
- 2010-12-15 HU HUE10796247A patent/HUE038042T2/hu unknown
- 2010-12-15 PL PL10796247T patent/PL2513070T3/pl unknown
- 2010-12-15 MX MX2012006725A patent/MX2012006725A/es active IP Right Grant
- 2010-12-15 WO PCT/US2010/060439 patent/WO2011084453A1/en not_active Ceased
- 2010-12-15 KR KR1020187022229A patent/KR102029611B1/ko active Active
- 2010-12-15 DK DK10796247.4T patent/DK2513070T3/en active
- 2010-12-15 EP EP10796247.4A patent/EP2513070B1/en active Active
- 2010-12-15 CN CN201080063893.4A patent/CN102753539B/zh active Active
- 2010-12-15 JP JP2012544740A patent/JP5634526B2/ja active Active
- 2010-12-15 RU RU2012129930/04A patent/RU2564661C2/ru active
- 2010-12-15 CA CA2783468A patent/CA2783468C/en active Active
- 2010-12-15 KR KR1020127018388A patent/KR20120107493A/ko not_active Ceased
- 2010-12-15 AU AU2010340055A patent/AU2010340055B2/en active Active
- 2010-12-15 US US13/515,508 patent/US8912335B2/en active Active
- 2010-12-15 NO NO10796247A patent/NO2513070T3/no unknown
-
2014
- 2014-10-30 US US14/528,163 patent/US9126959B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013514367A5 (enExample) | ||
| JP2012532848A5 (enExample) | ||
| JP2012041349A5 (enExample) | ||
| JP2016505614A5 (enExample) | ||
| RU2012129930A (ru) | Соли тиазолидиндиона со сниженным сродством к ppar для лечения нарушений обмена веществ | |
| JP2011513305A5 (enExample) | ||
| JP2016503793A5 (enExample) | ||
| IN2014CN00794A (enExample) | ||
| JP2014525420A5 (enExample) | ||
| JP2011522789A5 (enExample) | ||
| JP2016006118A5 (enExample) | ||
| JP2013544860A5 (enExample) | ||
| JP2014532060A5 (enExample) | ||
| JP2013544276A5 (enExample) | ||
| JP2016040288A5 (enExample) | ||
| JP2013531031A5 (enExample) | ||
| JP2013540713A5 (enExample) | ||
| JP2014508811A5 (enExample) | ||
| RU2007139634A (ru) | Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения | |
| JP2011500550A5 (enExample) | ||
| JP2006522035A5 (enExample) | ||
| CO6251243A2 (es) | Nuevos inhibidores macrocíclicos de la replicación del virus de hepatitis c | |
| JP2011504903A5 (enExample) | ||
| JP2012140436A5 (ja) | 物質 | |
| JP2011516610A5 (enExample) |